Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-09-01
|
| Series: | Retrovirology |
| _version_ | 1818862475577131008 |
|---|---|
| author | Katinger D Wagner A Luque I Crespillo S Conejero-Lara F Roger M Martin C Mouz N Mourao S Farsang A Notka F Malcolm K Bosquet N Le Grand R Moog C Cope A Shattock R Lewis DJ El Habib R |
| author_facet | Katinger D Wagner A Luque I Crespillo S Conejero-Lara F Roger M Martin C Mouz N Mourao S Farsang A Notka F Malcolm K Bosquet N Le Grand R Moog C Cope A Shattock R Lewis DJ El Habib R |
| author_sort | Katinger D |
| collection | DOAJ |
| first_indexed | 2024-12-19T10:00:28Z |
| format | Article |
| id | doaj.art-8578cf8df776487b974577fe282e9142 |
| institution | Directory Open Access Journal |
| issn | 1742-4690 |
| language | English |
| last_indexed | 2024-12-19T10:00:28Z |
| publishDate | 2012-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Retrovirology |
| spelling | doaj.art-8578cf8df776487b974577fe282e91422022-12-21T20:26:40ZengBMCRetrovirology1742-46902012-09-019Suppl 2P35410.1186/1742-4690-9-S2-P354Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humansKatinger DWagner ALuque ICrespillo SConejero-Lara FRoger MMartin CMouz NMourao SFarsang ANotka FMalcolm KBosquet NLe Grand RMoog CCope AShattock RLewis DJEl Habib R |
| spellingShingle | Katinger D Wagner A Luque I Crespillo S Conejero-Lara F Roger M Martin C Mouz N Mourao S Farsang A Notka F Malcolm K Bosquet N Le Grand R Moog C Cope A Shattock R Lewis DJ El Habib R Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans Retrovirology |
| title | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_full | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_fullStr | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_full_unstemmed | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_short | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_sort | liposomal formulation of gp41 derivate with adjuvant mpla vaccine design immunogenicity in animals and safety in humans |
| work_keys_str_mv | AT katingerd liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT wagnera liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT luquei liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT crespillos liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT conejerolaraf liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT rogerm liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT martinc liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT mouzn liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT mouraos liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT farsanga liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT notkaf liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT malcolmk liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT bosquetn liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT legrandr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT moogc liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT copea liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT shattockr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT lewisdj liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT elhabibr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans |